Lescol sNDA For Post-Angioplasty Adds 1 Mil. Potential Patients Per Year
Executive Summary
Reliant will target the 1 mil. U.S. patients who undergo angioplasty procedures each year who could benefit from Lescol (fluvastatin) and Lescol XL after approval of an expanded indication for the statin May 27
You may also be interested in...
Alkermes/Reliant Merger: Can Lescol Follow Altace Model?
Alkermes hopes Lescol will follow the model of King's Altace as a late bloomer in the cardiovascular market following the proposed acquisition of Reliant Pharmaceuticals
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials